ArticlePloS one2026
Revisiting fatty acid-mediated antibody purification from plasma with insights into selectivity and protein integrity.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic antibodies play an essential role in modern biopharmaceuticals, with polyclonal antibodies (pAbs) remaining indispensable for applications such as toxin and virus neutralization. However, pAb purification is complicated by serum-derived contaminants. Selective impurity precipitation using caprylic acid (C8) or sodium caprylate (NaC8) provides an effective strategy for obtaining high-purity antibody preparations and serves as a low-cost, scalable non-chromatographic alternative. However, the influence of fatty acid chain length and ionic form on differential precipitation remains poorly understood. Here, we systematically evaluated free fatty acids with varying chain length (C8-C10) and their corresponding sodium salts for pAb purification. Using model proteins, free fatty acids exhibited greater selectivity than their salt forms, and precipitation efficiency decreased with increasing chain length (C8 > C9 > C10). Importantly, C9 at 2% (v/v) provided a favorable balance between impurity removal and γ-globulin retention, achieving effective depletion of albumin while minimizing antibody loss relative to conventional C8 precipitation. Multi-spectroscopic analyses confirmed that γ-globulin maintained its native structure following fatty acid-based precipitation. When applied to the fractionation of IgG from hyperimmunized equine plasma, C9 achieved impurity reduction and IgG homogeneity comparable to conventional C8 treatment while preserving antigen-binding avidity. Collectively, these findings identify C9 as a selective and function-preserving precipitant with potential as an efficient and scalable pretreatment step in polyclonal antibody purification workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.